Derek Murphy
Internal Medicine · Noblesville, INNPI 1619014628
Payments from drug & device makers
Across 886 payments — averaging $11.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Vanda Pharmaceuticals Inc.$1K
- Lilly USA, LLC$670
- Esperion Therapeutics, Inc.$628
- Novo Nordisk$419
- Antares Pharma, Inc.$398
- plus $5K from 51 others
What the payments were for
- Food & beverage$10,31099%
- Education$1091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zenzedi$102
How this compares
$10,418 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 148 | $187,455 |
| OzempicSemaglutide | 81 | $84,672 |
| VraylarCariprazine Hcl | 32 | $55,131 |
| OtezlaApremilast | 11 | $49,370 |
| JanuviaSitagliptin Phosphate | 36 | $40,052 |
| JardianceEmpagliflozin | 41 | $38,587 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $17,334 |
| MyrbetriqMirabegron | 17 | $16,484 |
| VascepaIcosapent Ethyl | 19 | $14,260 |
| Repatha SureclickEvolocumab | 15 | $11,391 |
| SeglentisTramadol Hcl/Celecoxib | 21 | $10,884 |
| TrintellixVortioxetine Hydrobromide | 14 | $10,795 |
| EdarbiAzilsartan Medoxomil | 20 | $8,918 |
| NexletolBempedoic Acid | 13 | $7,655 |
| XyostedTestosterone Enanthate | 12 | $7,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $670 | $187,455148 claims |
| Novo NordiskOzempic | $419 | $84,67281 claims |
| AbbVieVraylar, Synthroid, Armour Thyroid | $2,318 | $60,63099 claims |
| AmgenOtezla | $165 | $49,37011 claims |
| MerckJanuvia, Belsomra | $271 | $44,83347 claims |
| Boehringer IngelheimJardiance | $391 | $38,58741 claims |
| GSKTrelegy Ellipta | $145 | $17,33417 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $16,48417 claims |
| Kowa Pharmaceuticals America, Inc.Seglentis | $260 | $10,88421 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $54 | $10,79514 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $272 | $8,91820 claims |
| Esperion Therapeutics, Inc.Nexletol | $628 | $7,65513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Noblesville
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.